Loading company…
Pahr Therapeutics develops treatments for pulmonary arterial hypertension.
Founded in 2025 and based in Boston, Pahr Therapeutics is a clinical-stage biotechnology company developing treatments for pulmonary arterial hypertension. RA Capital Management, AN Venture Partners and The University of Tokyo Edge Capital Partners invested USD 14.00 mn in Seed funding in July 2025. The funding will support development of PAH treatments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in